Philips enters into collaboration with Janssen to develop new handheld blood test
Royal Philips announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V.. The collaboration aims to develop a new handheld blood test to provide doctors with a novel tool to improve the care of patients with neuropsychiatric disorders.
The collaboration unites Philips’ expertise in point-of-care testing and monitoring applications for the hospital and the home, with Janssen’s strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for the development and manufacturing of the handheld test. The test will be based on Philips’ Minicare system, which is currently under development. Janssen will be responsible for the clinical studies to validate the test, as well as the commercialization of the final product.
“Our technology can play an important role in the management of chronic diseases in the hospital and the home,” said Frans van Houten, CEO Royal Philips. “Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform.” Mr. Van Houten added: “Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software, can be tailored to a wide range of other pharmaceuticals.”
The blood test will be based on Philips’ Minicare I-20 system for immunoassays, which consists of a handheld analyzer, dedicated software and a single use, disposable cartridge containing the application specific test. Based on Philips’ proprietary biosensor technology, the Minicare I -20 system is being developed to detect multiple target molecules at low concentrations within the same blood sample and to show the results on the analyzer display within minutes.
The Minicare activities are part of Philips’ Handheld Diagnostics business that has its headquarters and manufacturing lines at the High Tech Campus in Eindhoven, the Netherlands. The business will be expanding its production capacity in light of the new partnership.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Sigma-Aldrich strengthens position in RNAi and cell-based assays
Watching the production of new proteins in live cells
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen
Scientists X-ray chocolate
AI-based analysis system for the diagnosis of breast cancer - For the first time, morphological, molecular and histological data are integrated in a single analysis
New organ-on-chip pilot seeks to reduce animal testing in consumer health industry - Cooperation between Bayer, the start-ups esqLABS and Dynamic42, and Placenta Lab of Jena University Hospital
A vast viral world in wastewater - How metagenomic sequencing helps to understand the spread of viruses
Atomic-scale view of bacterial proteins offers path to new tuberculosis drugs
Ebolaviruses need very few mutations to cause disease in new host species
Sequenom to Begin Clinical Assessment of Noninvasive Screening Technology for Down Syndrome
